Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.

D. Gonzalez de Castro, P.A. Clarke, B. Al-Lazikani, P. Workman

Research output: Contribution to journalArticlepeer-review

175 Citations (Scopus)


The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution.
Original languageEnglish
Pages (from-to)252-259
Number of pages8
JournalClinical Pharmacology and Therapeutics
Issue number3
Publication statusPublished - Mar 2013


  • Biomarkers, Tumor
  • Drug Resistance, Neoplasm
  • Humans
  • Medical Oncology
  • Neoplasms
  • Pathology, Molecular
  • Precision Medicine
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf


Dive into the research topics of 'Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.'. Together they form a unique fingerprint.

Cite this